The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Teva- Pharmaceutical Industries Ltd. ADR shares valued at $952,464 were sold by Kalif Eliyahu Sharon on Jun 12 ’25. At $17.08 per share, Kalif Eliyahu Sharon sold 55,775 shares. The insider’s holdings dropped to 403,288 shares worth approximately $6.86 million following the completion of this transaction.
Also, Kalif Eliyahu Sharon purchased 55,775 shares, netting a total of over 952,466 in proceeds.
Before that, Shields Matthew had sold 6,206 shares from its account. In a trade valued at $105,628, the EVP, Global Operations traded Teva- Pharmaceutical Industries Ltd. ADR shares for $17.02 each. Upon closing the transaction, the insider’s holdings decreased to 6,206 shares, worth approximately $0.17 million.
As published in their initiating research note from Goldman on June 06, 2025, Teva- Pharmaceutical Industries Ltd. ADR [TEVA] has been a Buy and the price target has been revised to $24. Analysts at Truist started covering the stock with ‘”a Buy”‘ outlook in a report released in late May. As of May 12, 2025, JP Morgan has increased its “Neutral” rating to a “an Overweight” for TEVA. Earlier on July 10, 2024, Argus upgraded its rating. Their new recommendation was “a Buy” for TEVA stock which previously was a “a Hold”.
Analyzing TEVA Stock Performance
On last trading session,, Teva- Pharmaceutical Industries Ltd. ADR [NYSE: TEVA] plunged -0.53% to $17.0. The stock’s lowest price that day was $16.85, but it reached a high of $17.18 in the same session. During the last five days, there has been a surge of approximately 0.65%. Over the course of the year, Teva- Pharmaceutical Industries Ltd. ADR shares have jumped approximately 0.24%. Shares of the company reached a 52-week high of $22.40 on 01/28/25 and a 52-week low of $12.47 on 04/10/25.
Support And Resistance Levels for Teva- Pharmaceutical Industries Ltd. ADR (TEVA)
According to the 24-hour chart, there is a support level at 16.84, which, if violated, would cause prices to drop to 16.68. In the upper region, resistance lies at 17.17. The next price resistance is at 17.34. RSI (Relative Strength Index) is 49.29 on the 14-day chart, showing neutral technical sentiment.
Is Teva- Pharmaceutical Industries Ltd. ADR subject to short interest?
Stocks of Teva- Pharmaceutical Industries Ltd. ADR saw a sharp rise in short interest on 2025-05-30 jumping by 7.24 million shares to 35.67 million. Data from Yahoo Finance shows that the short interest on 2025-04-30 was 28.43 million shares. A jump of 20.3% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 2.61 of the overall float, the days-to-cover ratio (short ratio) jumped to 2.61.
Which companies own the most shares of Teva- Pharmaceutical Industries Ltd. ADR (TEVA)?
In terms of Teva- Pharmaceutical Industries Ltd. ADR share price expectations, FactSet research, analysts set an average price target of 22 in the next 12 months, up nearly 28.73% from the previous closing price of $17.09. Analysts anticipate Teva- Pharmaceutical Industries Ltd. ADR stock to reach 28 by 2025, with the lowest price target being 10. In spite of this, 8 analysts ranked Teva- Pharmaceutical Industries Ltd. ADR stock as Buy at the end of 2025. On March 08, 2024, JP Morgan assigned a price target of “a Neutral” to the stock and upgraded coverage with a $14.
